A Phase 1 interventional study of CP-690,550 and Placebo in Healthy, sponsored by Pfizer. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-16.
Sponsored by Pfizer · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
ICH E14 recommends that a thorough QT/QTc (TQT) study should be performed to determine whether intensive monitoring of QT interval in target patient populations is required during later stages of development. The current study is designed to ascertain whether CP-690,550 is associated with QTc prolongation.
The current study is designed to ascertain whether CP-690,550 is associated with QTc prolongation
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CP-690,550
Drug: Placebo
Drug: Moxifloxacin
Single dose 100 mg (5 x 20 mg tablets)
Single dose placebo tablets (5 tablets)
Single dose Avelox 400 mg tablet
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.25 Hour Post-Dose
Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to the beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as Least Squares (LS) mean difference (CP-690,550 minus Placebo, baseline-adjusted).
Time frame: 0.25 hour post-dose
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.5 Hour Post-Dose
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
Time frame: 0.5 hour post-dose
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 1 Hour Post-Dose
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
Time frame: 1 hour post-dose
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 2 Hours Post-Dose
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
Time frame: 2 hours post-dose
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 4 Hours Post-Dose
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
Time frame: 4 hours post-dose
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 8 Hours Post-Dose
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
Time frame: 8 hours post-dose
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 12 Hours Post-Dose
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
Time frame: 12 hours post-dose
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 16 Hours Post-Dose
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
Time frame: 16 hours post-dose
Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 24 Hours Post-Dose
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
Time frame: 24 hours post-dose
Mean Time-Matched Difference in QTcF Intervals Between Moxifloxacin Compared to Placebo
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (moxifloxacin minus Placebo, baseline-adjusted).
Time frame: 2 hours post-dose
Mean Time-Matched Difference in QTcB Intervals Between CP-690,550 Compared to Placebo
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Bazett's formula (QTcB = QT divided by square root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
Time frame: 0.25, 0.5, 1, 2, 4, 8, 12, 16, and 24 hours post-dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for CP-690,550
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CP-690,550
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of CP-690,550
Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550
Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Plasma Decay Half-Life (t1/2) of CP-690,550
Plasma decay half-life is the time measured for the plasma concentration of drug to decrease by one half.
Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of CP-690,550 by Cytochrome P450 2C19 (CYP2C19) Genotype
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. AUC (0 - ∞) categorized by genotype into poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.
Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of CP-690,550 by CYP2C19 Genotype
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. AUClast categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.
Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of CP-690,550 by CYP2C19 Genotype
Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. Cmax categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.
Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) of CP-690,550 by CYP2C19 Genotype
Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. Tmax categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.
Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
Plasma Decay Half-Life (t1/2) of CP-690,550 by CYP2C19 Genotype
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. t1/2 categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.
Time frame: 0 (pre-dose), and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hours post-dose
| Milestone | CP-690,550 100 mg Then Placebo Then Moxifloxacin 400 mg | CP-690,550 100 mg Then Moxifloxacin 400 mg Then Placebo | Placebo Then CP-690,550 100 mg Then Moxifloxacin 400 mg | Placebo Then Moxifloxacin 400 mg Then CP-690,550 100 mg | Moxifloxacin 400 mg Then CP-690,550 100 mg Then Placebo | Moxifloxacin 400 mg Then Placebo Then CP-690,550 100 mg |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 | 10 | 10 |
| Completed | 10 | 10 | 10 | 10 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | CP-690,550 100 mg Then Placebo Then Moxifloxacin 400 mg | CP-690,550 100 mg Then Moxifloxacin 400 mg Then Placebo | Placebo Then CP-690,550 100 mg Then Moxifloxacin 400 mg | Placebo Then Moxifloxacin 400 mg Then CP-690,550 100 mg | Moxifloxacin 400 mg Then CP-690,550 100 mg Then Placebo | Moxifloxacin 400 mg Then Placebo Then CP-690,550 100 mg |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 | 10 | 10 |
| Completed | 10 | 10 | 10 | 10 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | CP-690,550 100 mg Then Placebo Then Moxifloxacin 400 mg | CP-690,550 100 mg Then Moxifloxacin 400 mg Then Placebo | Placebo Then CP-690,550 100 mg Then Moxifloxacin 400 mg | Placebo Then Moxifloxacin 400 mg Then CP-690,550 100 mg | Moxifloxacin 400 mg Then CP-690,550 100 mg Then Placebo | Moxifloxacin 400 mg Then Placebo Then CP-690,550 100 mg |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 | 10 | 10 |
| Completed | 10 | 10 | 10 | 10 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | CP-690,550 100 mg Then Placebo Then Moxifloxacin 400 mg | CP-690,550 100 mg Then Moxifloxacin 400 mg Then Placebo | Placebo Then CP-690,550 100 mg Then Moxifloxacin 400 mg | Placebo Then Moxifloxacin 400 mg Then CP-690,550 100 mg | Moxifloxacin 400 mg Then CP-690,550 100 mg Then Placebo | Moxifloxacin 400 mg Then Placebo Then CP-690,550 100 mg |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 | 10 | 10 |
| Completed | 10 | 10 | 10 | 10 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | CP-690,550 100 mg Then Placebo Then Moxifloxacin 400 mg | CP-690,550 100 mg Then Moxifloxacin 400 mg Then Placebo | Placebo Then CP-690,550 100 mg Then Moxifloxacin 400 mg | Placebo Then Moxifloxacin 400 mg Then CP-690,550 100 mg | Moxifloxacin 400 mg Then CP-690,550 100 mg Then Placebo | Moxifloxacin 400 mg Then Placebo Then CP-690,550 100 mg |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 | 10 | 10 |
| Completed | 10 | 10 | 10 | 10 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to the beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as Least Squares (LS) mean difference (CP-690,550 minus Placebo, baseline-adjusted).
| milliseconds (msec) | CP-690,550 100 mg | Placebo |
|---|---|---|
| Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.25 Hour Post-Dose | 416.48 ± 0.8823 | 417.77 ± 0.8823 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
| msec | CP-690,550 100 mg | Placebo |
|---|---|---|
| Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.5 Hour Post-Dose | 414.70 ± 0.8823 | 416.12 ± 0.8823 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
| msec | CP-690,550 100 mg | Placebo |
|---|---|---|
| Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 1 Hour Post-Dose | 414.69 ± 0.8823 | 416.98 ± 0.8823 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
| msec | CP-690,550 100 mg | Placebo |
|---|---|---|
| Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 2 Hours Post-Dose | 413.70 ± 0.8823 | 415.05 ± 0.8823 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
| msec | CP-690,550 100 mg | Placebo |
|---|---|---|
| Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 4 Hours Post-Dose | 416.83 ± 0.8823 | 415.76 ± 0.8823 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
| msec | CP-690,550 100 mg | Placebo |
|---|---|---|
| Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 8 Hours Post-Dose | 409.25 ± 0.8823 | 408.39 ± 0.8823 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
| msec | CP-690,550 100 mg | Placebo |
|---|---|---|
| Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 12 Hours Post-Dose | 411.39 ± 0.8823 | 410.24 ± 0.8823 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
| msec | CP-690,550 100 mg | Placebo |
|---|---|---|
| Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 16 Hours Post-Dose | 415.87 ± 0.8823 | 413.72 ± 0.8823 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
| msec | CP-690,550 100 mg | Placebo |
|---|---|---|
| Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 24 Hours Post-Dose | 412.53 ± 0.8823 | 411.18 ± 0.8823 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Data is reported as LS mean difference (moxifloxacin minus Placebo, baseline-adjusted).
| msec | Moxifloxacin 400 mg | Placebo |
|---|---|---|
| Mean Time-Matched Difference in QTcF Intervals Between Moxifloxacin Compared to Placebo | 426.34 ± 0.8823 | 415.05 ± 0.8823 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The QT interval was adjusted for RR interval using the QT and RR from each ECG by Bazett's formula (QTcB = QT divided by square root of RR). Data is reported as LS mean difference (CP-690,550 minus Placebo, baseline-adjusted).
| msec | CP-690,550 100 mg | Placebo |
|---|---|---|
| 0.25 Hour Post-Dose | 416.40 ± 1.1139 | 416.24 ± 1.1139 |
| 0.5 Hour Post-Dose | 416.69 ± 1.1139 | 414.91 ± 1.1139 |
| 1 Hour Post-Dose | 417.98 ± 1.1139 | 414.99 ± 1.1139 |
| 2 Hours Post-Dose | 414.54 ± 1.1139 | 413.46 ± 1.1139 |
| 4 Hours Post-Dose | 417.26 ± 1.1139 | 415.10 ± 1.1139 |
| 8 Hours Post-Dose | 412.91 ± 1.1139 | 412.86 ± 1.1139 |
| 12 Hours Post-Dose | 416.76 ± 1.1139 | 416.27 ± 1.1139 |
| 16 Hours Post-Dose | 416.44 ± 1.1139 | 414.33 ± 1.1139 |
| 24 Hours Post-Dose | 413.93 ± 1.1139 | 413.14 ± 1.1139 |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| nanogram*hour/milliliter (ng*hr/mL) | CP-690,550 100 mg |
|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for CP-690,550 | 2682.6 ± 778.15 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
| ng*hr/mL | CP-690,550 100 mg |
|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CP-690,550 | 2669.7 ± 771.02 |
| nanogram/milliliter (ng/mL) | CP-690,550 100 mg |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of CP-690,550 | 563.5 ± 199.23 |
| hours | CP-690,550 100 mg |
|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550 | 1.000 (0.30 to 4.08) |
Plasma decay half-life is the time measured for the plasma concentration of drug to decrease by one half.
| hours | CP-690,550 100 mg |
|---|---|
| Plasma Decay Half-Life (t1/2) of CP-690,550 | 3.284 ± 0.4871 |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. AUC (0 - ∞) categorized by genotype into poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.
| ng*hr/mL | CP-690,550 100 mg |
|---|---|
| Poor Metabolizer | 3127.5 ± 373.18 |
| Extensive Metabolizer | 2683.5 ± 787.75 |
| Ultra Extensive Metabolizer | 1677.7 ± 637.68 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. AUClast categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.
| ng*hr/mL | CP-690,550 100 mg |
|---|---|
| Poor Metabolizer | 3114.3 ± 366.68 |
| Extensive Metabolizer | 2670.2 ± 780.41 |
| Ultra Extensive Metabolizer | 1673.1 ± 636.30 |
Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. Cmax categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.
| ng/mL | CP-690,550 100 mg |
|---|---|
| Poor Metabolizer | 647.4 ± 281.69 |
| Extensive Metabolizer | 565.0 ± 185.62 |
| Ultra Extensive Metabolizer | 346.9 ± 214.25 |
Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. Tmax categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.
| hours | CP-690,550 100 mg |
|---|---|
| Poor Metabolizer | 0.500 (0.30 to 4.03) |
| Extensive Metabolizer | 1.000 (0.30 to 4.08) |
| Ultra Extensive Metabolizer | 2.000 (2.00 to 2.00) |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Variation in CYP2C19 gene affected the pharmacokinetics of CP-690,550. t1/2 categorized by genotype as poor metabolizer, extensive metabolizer and ultra extensive metabolizer of CYP2C19.
| hours | CP-690,550 100 mg |
|---|---|
| Poor Metabolizer | 3.005 ± 0.3566 |
| Extensive Metabolizer | 3.320 ± 0.5006 |
| Ultra Extensive Metabolizer | 3.201 ± 0.1821 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CP-690,550 100 mg | — | 0/60 (0%) | 32/60 (53.3%) |
| Placebo | — | 0/60 (0%) | 6/60 (10%) |
| Moxifloxacin | — | 0/60 (0%) | 10/60 (16.7%) |
| Event | CP-690,550 100 mg | Placebo | Moxifloxacin |
|---|---|---|---|
| NauseaGastrointestinal disorders | 17/60 | 0/60 | 0/60 |
| HeadacheNervous system disorders | 17/60 | 1/60 | 2/60 |
| VomitingGastrointestinal disorders | 6/60 | 0/60 | 0/60 |
| Abdominal discomfortGastrointestinal disorders | 3/60 | 0/60 | 0/60 |
| Abdominal painGastrointestinal disorders | 2/60 | 0/60 | 1/60 |
| DiarrhoeaGastrointestinal disorders | 2/60 | 0/60 | 2/60 |
| ToothacheGastrointestinal disorders | 2/60 | 0/60 | 0/60 |
| DizzinessNervous system disorders | 2/60 | 0/60 | 2/60 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 1/60 | 1/60 | 2/60 |
| PalpitationsCardiac disorders | 1/60 | 0/60 | 0/60 |
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 32.7 ± 9.2 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 28 |
| Male | 32 |
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2007 to primary completion in Feb 2008, 3 months.
Results were first posted in Sep 2020, 12 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib